Navigation Links
OriGene Releases 1500 TrueMAB™ Monoclonal Antibodies
Date:1/20/2011

ROCKVILLE, Md., Jan. 20, 2011 /PRNewswire/ -- OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity. Greater than 50% of all TrueMAB antibodies are validated for immunohistochemistry and for flow cytomtery applications.

Monoclonal antibodies have become invaluable tools for researchers developing diagnostic tests and novel therapeutics.  In 2010, OriGene announced its commitment to build the world's largest monoclonal antibody facility capable of producing over 20,000 TrueMAB antibodies per year. Recently, OriGene has released its 1,500th monoclonal antibody and hybridoma cell line under the TrueMAB brand name.

"We are extremely pleased with OriGene's progress in achieving this significant milestone in less than a year. Our antibody performance and hybridoma development capabilities have uniquely positioned us as an instrumental partner for diagnostic and research assay development. We fully anticipate releasing 400-500 new mouse monoclonal antibodies per month by end of 2011 as we head towards our ultimate goal," commented Wei-Wu He, Ph.D., CEO & Chairman, OriGene Technologies.

TrueMAB antibodies and hybridoma cell lines from OriGene are generated using OriGene's large collection of full-length human proteins as primary antigens that have been affinity purified under native conditions to preserve natural protein conformations.  As a result, TrueMAB antibodies provide high sensitivity and specificity for the recognition of native epitopes on the protein's natural conformational structure.  With the introduction of TrueMAB antibodies, each included with an over-expression control protein lysate, OriGene now provides higher quality and greater numbers of monoclonal antibodies for diagnostic and research applications.

All TrueMAB antibodies are routinely validated for critical applications such as immunohistochemistry, immunofluorescent staining, flow cytometry, immunoprecipitation, and Western blot analysis. The hybridoma cell lines are available for immediate licensing to partnering organizations.

To learn more about OriGene's TrueMAB mouse monoclonal antibody development program and hybridoma cell line licensing opportunities, please visit www.origene.com/antibody/TrueMAB or contact businessdev@origene.com.

About OriGene Technologies

OriGene Technologies, Inc., is a gene centric life sciences company dedicated to support academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery.  OriGene develops proteins, antibodies, and other molecular tools to allow researchers to analyze their data on a multiplex level. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 5,000 purified human proteins, high quality monoclonal antibodies (TrueMAB™), 100,000 highly validated human tissues, and protein microarray products and services.  OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. For more information, visit www.origene.com.


'/>"/>
SOURCE OriGene Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
2. OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
3. OriGene Launches 5,000 Purified Human Proteins from HEK293 Cells
4. OriGene Technologies Acquires Marligen Biosciences
5. OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome
6. OriGene Technologies, Inc. to Build the Worlds Largest TrueMAB(TM) Monoclonal Antibody Facility in Wuxi, China
7. OriGene Technologies Launches Over 5,000 Heavy Isotope Labeled Full-Length Human Proteins as Quantitative Internal Standards for SRM/MRM Mass Spectrometry
8. Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution
9. Aureus Pharma Releases New Unified Knowledge Database
10. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
11. Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Patient ... developed with Wi-Fi connectivity to reduce the amount of wiring in a healthcare ... addition, compact mobile devices including infusion pumps, heart and hypertension monitoring, glucose monitoring, ...
(Date:5/23/2017)... ... 2017 , ... Firmex today announced the general ... for organizations to send and gather large files and confidential documents beyond the ... size limitations. , Using the same market-tested infrastructure as Firmex’s flagship Virtual ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... source of human cardiovascular cells for research and the development of cardiac ... possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation ...
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions has been ranked as ... Globe™ for Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who ... perform against those strategies. NetDimensions’ ranking as a Leader due to its strengths ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):